Notch Inhibitor in Advanced Cancer

Phase 1 Completed 35 enrolled Eli Lilly and Company

NaSingle-groupOpen-labelTreatment

Summary

The objective of this phase 1 study is to evaluate the safety and tolerability of Notch Inhibitor in participants with advanced cancer. This study includes dose escalation and dose confirmation components.

Timeline

Start: 2010-07
Primary completion: 2012-08
Completion: 2012-08

Publications

Pant S, Jones SF, Kurkjian CD, Infante JR, Moore KN, Burris HA, McMeekin DS, Benhadji KA, Patel BKR, Frenzel MJ, Kursar JD, Zamek-Gliszczynski MJ, Yuen ESM, Chan EM, Bendell JC. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur J Cancer. 2016 Mar;56:1-9. doi: 10.1016/j.ejca.2015.11.021. Epub 2016 Jan 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY900009	Small molecule	2 mg	Oral
Subject	LY900009	Small molecule	4 mg	Oral
Subject	LY900009	Small molecule	8 mg	Oral
Subject	LY900009	Small molecule	15 mg	Oral
Subject	LY900009	Small molecule	30 mg	Oral
Subject	LY900009	Small molecule	45 mg	Oral
Subject	LY900009	Small molecule	60 mg	Oral

Notch Inhibitor in Advanced Cancer

Summary

Timeline

Publications

Drugs

Indications